MGST2

Across TCGA pan-cancer cohorts, MGST2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MGST2 data layer compared with 28 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MGST2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated MGST2 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

HNSC, LUAD, and LSCC are the cancer types where MGST2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Tertile	II,III,IV	0.901	0.564	.001	24	view →
LUAD	DFS	Quartile	II,III,IV	0.757	0.988	.011	8	view →
LSCC	DFS	Median	III,IV	0.436	0.831	.015	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

MGST2–HNSC (OS)

Open the HNSC breakdown →